Sun Pharma open to enhance manufacturing footprint in US
New Delhi: Sun Pharma has kept its options open on enhancing its manufacturing footprint in the U.S., even as the U.S. administration's 100% tariff on branded and patented medicines has created uncertainty for global drugmakers.
During an analyst call, Richard Ascroft, CEO for Sun Pharma’s North America business, said the company already has a manufacturing footprint in the U.S..
Read also: Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide
Sun Pharma is a specialty generics company with a presence in specialty, generics and consumer healthcare products. Sun Pharma’s global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. Its manufacturing facilities are spread across six continents.
Read also: Sun Pharma appoints Jeremy Allen as Vice President, Corporate Affairs for North America
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.